Previous 10 | Next 10 |
2024-06-04 09:00:06 ET Asthika Goonewardene from Truist Financial issued a price target of $88.00 for MRUS on 2024-06-04 08:08:00. The adjusted price target was set to $88.00. At the time of the announcement, MRUS was trading at $52.94. The overall price target consensus...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today a...
2024-05-30 03:10:38 ET More on Merus Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy) Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement Merus rallies on publication of oncology study abstracts Merus gets FDA breakthr...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg, M.D....
2024-05-28 21:15:01 ET Citigroup analyst issues BUY recommendation for MRUS on May 28, 2024 08:02PM ET. The previous analyst recommendation was Buy. MRUS was trading at $54.87 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
2024-05-28 16:12:04 ET More on Merus Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy) Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement Merus rallies on publication of oncology study abstracts Merus gets FDA breakthr...
2024-05-28 14:00:08 ET Etzer Darout from BMO Capital issued a price target of $84.00 for MRUS on 2024-05-28 11:51:00. The adjusted price target was set to $84.00. At the time of the announcement, MRUS was trading at $53.86. The overall price target consensus is at $61.75...
2024-05-28 12:00:11 ET Bradley Canino from Stifel Nicolaus issued a price target of $90.00 for MRUS on 2024-05-28 10:25:00. The adjusted price target was set to $90.00. At the time of the announcement, MRUS was trading at $54.8. The overall price target consensus is at $...
67% response rate observed among 24 evaluable patients Conference Call on Tuesday, May 28 th at 8 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage onco...
News, Short Squeeze, Breakout and More Instantly...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...
2024-07-13 04:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...